Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:MBRXNASDAQ:PPBTNASDAQ:RVPHNASDAQ:TNXP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMBRXMoleculin Biotech$1.00+0.3%$1.00$0.40▼$5.29$14.03M1.641.44 million shs136,008 shsPPBTPurple Biotech$2.21-1.3%$2.63$2.00▼$20.60$2.94M0.57268,698 shs55,821 shsRVPHReviva Pharmaceuticals$0.82+4.2%$0.88$0.49▼$4.28$38.21M0.081.13 million shs272,830 shsTNXPTonix Pharmaceuticals$18.93-1.1%$17.77$6.76▼$672.00$121.78M1.63794,334 shs431,506 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMBRXMoleculin Biotech-0.10%-0.79%+35.77%+25.56%-79.59%PPBTPurple Biotech-1.34%-5.96%-7.14%-26.33%+220,999,900.00%RVPHReviva Pharmaceuticals+4.27%-6.31%+54.25%-60.70%-71.01%TNXPTonix Pharmaceuticals-0.68%+4.91%-4.52%+52.74%-96.67%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationMBRXMoleculin Biotech2.7931 of 5 stars3.55.00.00.01.80.01.3PPBTPurple Biotech2.065 of 5 stars3.55.00.00.00.60.00.6RVPHReviva Pharmaceuticals2.4466 of 5 stars3.62.00.00.01.23.30.6TNXPTonix Pharmaceuticals2.4346 of 5 stars3.52.00.00.02.01.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMBRXMoleculin Biotech 3.00Buy$6.00498.80% UpsidePPBTPurple Biotech 3.00Buy$33.001,393.21% UpsideRVPHReviva Pharmaceuticals 3.29Buy$10.001,123.24% UpsideTNXPTonix Pharmaceuticals 3.00Buy$585.002,991.15% UpsideCurrent Analyst Ratings BreakdownLatest PPBT, RVPH, MBRX, and TNXP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/24/2025RVPHReviva PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.004/1/2025RVPHReviva PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $8.003/25/2025MBRXMoleculin BiotechMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$4.003/24/2025MBRXMoleculin BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.003/20/2025TNXPTonix PharmaceuticalsNoble FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$70.00 ➝ $70.003/3/2025MBRXMoleculin BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.002/12/2025MBRXMoleculin BiotechMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold(Data available from 5/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMBRXMoleculin BiotechN/AN/AN/AN/A$11.70 per shareN/APPBTPurple BiotechN/AN/AN/AN/A$27.18 per shareN/ARVPHReviva PharmaceuticalsN/AN/AN/AN/A$0.20 per shareN/ATNXPTonix Pharmaceuticals$10.09M12.06N/AN/A$5,751.80 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMBRXMoleculin Biotech-$29.77MN/A0.00N/AN/AN/A-157.44%-97.16%5/13/2025 (Estimated)PPBTPurple Biotech-$19.88M-$5.25N/AN/AN/AN/A-55.86%-44.67%5/20/2025 (Estimated)RVPHReviva Pharmaceuticals-$39.26M-$0.91N/AN/AN/AN/AN/A-252.53%5/13/2025 (Estimated)TNXPTonix Pharmaceuticals-$116.66M-$2,535.85N/AN/AN/A-1,197.86%-163.95%-118.88%5/12/2025 (Estimated)Latest PPBT, RVPH, MBRX, and TNXP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025MBRXMoleculin Biotech-$0.71N/AN/AN/AN/AN/A5/13/2025Q1 2025RVPHReviva Pharmaceuticals-$0.21N/AN/AN/AN/AN/A5/12/2025Q1 2025TNXPTonix Pharmaceuticals-$3.23N/AN/AN/A$2.55 millionN/A3/31/2025Q4 2024RVPHReviva Pharmaceuticals-$0.22-$0.15+$0.07-$0.15N/AN/A3/18/2025Q4 2024TNXPTonix Pharmaceuticals-$6.23-$9.77-$3.54-$9.77$3.20 million$2.58 million3/10/2025Q4 2024PPBTPurple Biotech-$0.22-$0.26-$0.04-$0.26N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthMBRXMoleculin BiotechN/AN/AN/AN/AN/APPBTPurple BiotechN/AN/AN/AN/AN/ARVPHReviva PharmaceuticalsN/AN/AN/AN/AN/ATNXPTonix PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMBRXMoleculin BiotechN/A2.082.08PPBTPurple BiotechN/A1.271.27RVPHReviva PharmaceuticalsN/A0.390.39TNXPTonix Pharmaceuticals0.073.332.81Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMBRXMoleculin Biotech15.52%PPBTPurple Biotech9.64%RVPHReviva Pharmaceuticals63.18%TNXPTonix Pharmaceuticals82.26%Insider OwnershipCompanyInsider OwnershipMBRXMoleculin Biotech1.90%PPBTPurple Biotech2.98%RVPHReviva Pharmaceuticals27.18%TNXPTonix Pharmaceuticals0.03%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMBRXMoleculin Biotech2014.00 million3.86 millionNot OptionablePPBTPurple Biotech201.33 million1.29 millionOptionableRVPHReviva Pharmaceuticals546.74 million24.35 millionOptionableTNXPTonix Pharmaceuticals506.44 million1.87 millionNot OptionablePPBT, RVPH, MBRX, and TNXP HeadlinesRecent News About These CompaniesTonix Pharmaceuticals (NASDAQ:TNXP) Trading 2.5% Higher - Here's WhyMay 7 at 3:40 PM | marketbeat.comTonix Pharmaceuticals (TNXP) Expected to Announce Quarterly Earnings on MondayMay 7 at 8:12 AM | marketbeat.comGeode Capital Management LLC Purchases 1,855,907 Shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)May 6 at 3:10 AM | marketbeat.comTonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Short Interest UpdateMay 5, 2025 | marketbeat.comTonix Pharmaceuticals Holding Corp Share Chat (TNXP.US)May 3, 2025 | lse.co.ukTonix Pharmaceuticals Presented Preclinical Data on Gastric Cancer Models at the American Association for Cancer Research (AACR) 2025 Annual MeetingApril 29, 2025 | globenewswire.comTonix Pharmaceuticals culls cocaine intoxication trial amid enrollment woesApril 28, 2025 | fiercebiotech.comTonix Pharmaceuticals present data on potential Mpox vaccine TNX-801April 26, 2025 | markets.businessinsider.comWhy Tonix Pharmaceuticals Holding Corp.’s (TNXP) Stock Is Up 7.99%April 24, 2025 | aaii.comTonix Pharmaceuticals Presented Data on Potential Mpox Vaccine TNX-801 at World Vaccine Congress Washington 2025April 24, 2025 | globenewswire.comTonix Pharmaceuticals (TNXP) to Present at World Vaccine CongressApril 23, 2025 | gurufocus.comTonix Pharmaceuticals (TNXP) Falls Despite Market UpturnApril 23, 2025 | gurufocus.comTonix Pharmaceuticals to Present at World Vaccine Congress Washington 2025 on Novel Mpox VaccineApril 16, 2025 | quiverquant.comTonix Pharmaceuticals Announces Oral Presentation and Panel Participation at the World Vaccine Congress Washington 2025April 16, 2025 | globenewswire.comWhy Tonix Pharmaceuticals Corp. (TNXP) Went Down On Thursday?April 10, 2025 | insidermonkey.comTonix Pharmaceuticals, Makana to announce collaboration research agreementApril 9, 2025 | msn.comWhy Tonix Pharmaceuticals Holding Corp.’s (TNXP) Stock Is Down 10.75%April 9, 2025 | aaii.comTonix Pharmaceuticals and Makana Therapeutics Announce Collaboration Combining Tonix's Anti-CD40L Monoclonal Antibody (TNX-1500) with Makana's Genetically Engineered Organs in Preclinical and Clinical Xenotransplantation StudiesApril 9, 2025 | globenewswire.comWhy Tonix Pharmaceuticals Holding Corp.’s (TNXP) Stock Is Up 18.09%April 8, 2025 | aaii.comTonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on ...April 7, 2025 | gurufocus.comTonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the American Academy of Pain Medicine (AAPM) 2025 Annual MeetingApril 7, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePPBT, RVPH, MBRX, and TNXP Company DescriptionsMoleculin Biotech NASDAQ:MBRX$1.00 +0.00 (+0.29%) Closing price 05/8/2025 03:59 PM EasternExtended Trading$1.01 +0.01 (+1.30%) As of 07:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.Purple Biotech NASDAQ:PPBT$2.21 -0.03 (-1.34%) Closing price 05/8/2025 03:49 PM EasternExtended Trading$2.25 +0.04 (+1.63%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.Reviva Pharmaceuticals NASDAQ:RVPH$0.82 +0.03 (+4.19%) Closing price 05/8/2025 04:00 PM EasternExtended Trading$0.82 +0.01 (+0.92%) As of 06:15 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. Reviva Pharmaceuticals Holdings, Inc. was founded in 2018 and is headquartered in Cupertino, California.Tonix Pharmaceuticals NASDAQ:TNXP$18.92 -0.22 (-1.12%) Closing price 05/8/2025 03:59 PM EasternExtended Trading$18.81 -0.12 (-0.61%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates. The company's priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA. The company's rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS). Its immunology portfolio includes TNX-1500, which is a biologic to address organ transplant rejection and autoimmune diseases. The company's infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800 and TNX-1850, in development as a vaccine to protect against COVID-19. Its infectious disease development portfolio also comprises TNX-3900, and TNX-4200 are orally available CD45 antagonists in preclinical development. Tonix Pharmaceuticals Holding Corp. has collaboration agreement with Bilthoven Biologicals to advance TNX-801 mpox vaccine candidate; and with X-Chem, Inc. to develop broad-spectrum antivirals. The company was founded in 2007 and is headquartered in Chatham, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Is Energy Transfer Undervalued or a Value Trap? Carvana’s Stock Price Rebound Shifts Into a Higher Gear Why Investors Should Be Careful About AMC's Bitcoin Dreams Alphabet Slumps as Apple Eyes AI Search—Is the Sell-Off Overdone? Joby's Q1: Key Milestones Achieved as Path to Market Crystalizes Rockwell Automation: Tailwinds From Onshoring U.S. Production IBM's AI Offensive: Assessing IBM's Path to Renewed Growth Bloomin’ Brands Stock Drops on Weak Guidance and Demand Concerns Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
